Please provide your email address to receive an email when new articles are posted on . The interleukin-5 inhibitor benralizumab yielded durable remission rates in EGPA. The drug showed no new safety ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
GSK plc’s interleukin-5 (IL-5) portfolio got boost as depemokimab, an ultra-long-acting biologic targeting IL-5, hit its endpoints in two phase III trials in severe asthma, setting up potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback